276°
Posted 20 hours ago

Schwabe Pharma - Kaloba Cough & Cold Relief Syrup - Pelargonium Sidoides Root Extract - Traditionally Used for Common Cold, Runny Nose, Sore Throat, Blocked Nose, Cough - Sugar Free – 100ml

£39.5£79.00Clearance
ZTS2023's avatar
Shared by
ZTS2023
Joined in 2023
82
63

About this deal

No studies on the effect on the ability to drive and use machines have been performed. 4.8 Undesirable effects If you get any side-effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in this leaflet. You can also report side-effects directlyvia the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side-effectsyou can help provide more information on the safety of this medicine. Signs indicating changes in liver function have been reported after taking Kaloba;however, the causal relationship between these effects and the use of the product has not been demonstrated. After taking this product Unfortunately, it proved very difficult to interview patients who did not agree to participate in the trial. The two non-participants explained that they were both initially willing to participate, but one was not eligible and the second declined due to potential side effects (headaches), imminent holiday plans and she was not keen to commit to filling in a daily diary. Tell your doctor or pharmacist if any of the above side-effects becomes serious or if you notice any other side-effects not listed above.

HATRIC was approved by the Health Research Authority (17/SC/0653 HATRIC; IRAS Project ID: 230883; Sponsor’s Ref Number: 24375). HATRIC-Q was also approved by the HRA (HRA REC: 18/NE/0016; IRAS Project ID: 233467; University of Southampton REC number 29921). On advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA), this feasibility study is not classed as a Clinical Trial of an Investigational Medicinal Product (CTIMP) because the outcome measures do not include efficacy of the product and so a clinical trial authorisation (CTA) is not required for this feasibility trial. The sponsor of the trial was the University of Southampton with the coordination of the trial undertaken by the UK Clinical Research Collaboration registered Southampton Clinical Trials Unit (a NIHR CTU support funded Clinical Trials Unit). Participants in the HATRIC trial provided written consent. Those who took part in the qualitative interviews also provided verbal consent, because the interviews were conducted by telephone. This was approved by the ethics committee. Competing interests Transcripts were analysed using inductive thematic analysis, following the framework approach [ 37]. The transcripts were compared within and between each other to search for themes, which were then reviewed, defined and named. The analysis followed three key steps: Our results suggest that progression to a full randomised phase III trial is feasible. The feasibility trial has identified some key modifications which will be needed. It would be easier to choose only one formulation to test (liquid or tablet). Although most patients reported that they would prefer tablets, the Cochrane review [ 30] suggested that the liquid may be more effective. If the liquid is to be taken into a full trial, a more convenient dosage method may need to be provided as many patients struggled accurately to count 30 drops per dose. If a full study uses both liquid and tablet preparations, we would need to adapt the design to prevent imbalance in the antibiotic use. This could be achieved by individual randomisation (tablet/liquid/active/placebo) or through stratification of practices according to prior antibiotic prescribing history. Feasibility outcomes were: recruitment rate, withdrawal rate from the study, return rate of patient diaries, percentage of completion of patient diaries, compliance with medication according to diary data and returned medication, type of antibiotic prescription given (i.e. immediate/delayed/not given), percentage of patients who took antibiotics, time to antibiotic usage, mean symptom severity (at days 2–4), percentage of patients resolved, time to resolution of symptoms and duration of treatment with herbal medication. The minimum key outcome dataset from the diaries was considered to be [ 1] antibiotic use in the 28 days post randomisation, [ 2] no longer experiencing moderate symptoms for two consecutive days and [ 3] study medication use. A health economic study was a part of the feasibility study which aimed to develop the methods of data collection both for quality of life and for usage of key resources for the design of the future phase III trial. Whitehead A, Simpson C, Willcox M, Webley F, Hay AD, Butler C, et al. HATRIC: a study of Pelargonium sidoides root extract EPs®7630 (Kaloba®) for the treatment of acute cough due to lower respiratory tract infection in adults—study protocol for a double blind, placebo-controlled randomised feasibility trial. Pilot and Feasibility Studies. 2019;5(1):98.

Reporting of side-effects

Film-coating: Hypromellose 5 mPas, Macrogol 1500, iron oxide yellow E 172, iron oxide red E 172, titanium dioxide E 171, talc, simeticone, methylcellulose, sorbic acid. The necessary amount of drops may be taken directly from a spoon or, if preferred, can be mixed with half a glass of water and the contents of the entire glass should be drunk straightaway.

Harmful for those suffering from alcoholism. To be taken into account in children and high-risk groups such as patients with liver disease, or epilepsy. 4.5 Interaction with other medicinal products and other forms of interaction Parents often believe that the administration of honey to relieve cough and improve sleep quality at night is more desirable than the administration of drugs such as diphenhydramine or dextromethorphan. Moreover, evidence from some clinical studies support the use of honey to relieve cough. Results from a study comparing a single dose of honey, dextromethorphan and no treatment indicated that parents view honey as the most favourable treatment for symptomatic relief of nocturnal cough due to upper respiratory tract infection in children aged 2–18 years [ 10]. One of the primary benefits of pelargonium sidoides is their effectiveness in treating acute bronchitis. That is because it enhances the body’s natural healing ability. According to research, almost 50% of people with acute bronchitis who supplemented it entirely recovered their symptoms within a week. Some individuals experienced benefits within two to three days. Do not use this product after the expiry date. Return any out-of-date product to your pharmacist who will dispose of it for you. The expiry date is printed on the box and alsothe bottle label.It is recommended to continue treatment for several days after symptoms have subsided to avoid relapse. A. The leaves and other parts of the pelargonium sidoides herb have been traditionally used for medicinal purposes for a very long time. They have proven beneficial in many health conditions like tuberculosis, respiratory tract infections, diarrhoea, etc. In addition, its leaves also possess antifungal properties. Q. What is a pelargonium root? However, due to the potential influence of Kaloba on coagulation parameters, the possibility that this product enhances the effect of coagulation-inhibiting drugs such as warfarin in cases of simultaneous intake cannot be excluded (see section 4.3). 4.6 Pregnancy and lactation

If you experience fever, shortness of breath or bloody sputum, or if you notice signs of liver dysfunction (e.g. yellowing of the white skin of the eyes or skin), you must consult a doctor.Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol. 2008;119(3):420–33. This is the first feasibility trial to be conducted on the use of a herbal medicine for acute bronchitis in UK primary care. A strength of this trial is the use of both quantitative and qualitative methods to explore several feasibility aspects. The trial was not powered to detect effectiveness, so we are unable to comment on the effectiveness of the herbal medicine. However, there was no evidence of any serious side-effects due to the intervention and the patient withdrawal rate was low. Although the study was only open for 9 months as opposed to the 12 months initially planned, we recruited at a faster rate than anticipated.

Asda Great Deal

Free UK shipping. 15 day free returns.
Community Updates
*So you can easily identify outgoing links on our site, we've marked them with an "*" symbol. Links on our site are monetised, but this never affects which deals get posted. Find more info in our FAQs and About Us page.
New Comment